Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02554409 · ClinicalTrials.gov registry record

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

A clinical trial of Pregnancy and Influenza, sponsored by Sanofi Pasteur, a Sanofi Company.

Completed
Registry status
87
Enrollment target
5
Study locations

NCT02554409 is a study of Pregnancy and Influenza that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 87 participants, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02554409, a study of Pregnancy and Influenza, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.

COMPLETED
Registry status
87 participants
Enrollment target
5
Study locations

Study Summary

The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes on pregnant women exposed to Fluzone QIV-ID vaccine.

Conditions Studied

Interventions

  • BIOLOGICAL Quadrivalent Intradermal Influenza Vaccine (QIV)

Study Locations (5)

California

  • - San Diego

Florida

  • - Miami

New York

  • - Albany

Pennsylvania

  • - Philadelphia

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2015-10-13
Est. Completion 2019-04-30

Sponsor

Sanofi Pasteur, a Sanofi Company

153 total trials

What the Registry Record Tells You About NCT02554409

The ClinicalTrials.gov registry entry for NCT02554409 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (90% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which Quadrivalent Intradermal Influenza Vaccine (QIV) is the first listed.

NCT02554409 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT02554409 about?

NCT02554409 is a clinical study titled "Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry". The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes on pregna...

What is the current status of trial NCT02554409?

This trial is currently completed. The enrollment target is 87 participants. The study started on 2015-10-13. Estimated completion is 2019-04-30.

What conditions does trial NCT02554409 study?

This clinical trial studies the following conditions: Pregnancy, Influenza.

What interventions are being tested in trial NCT02554409?

The interventions under investigation include: Quadrivalent Intradermal Influenza Vaccine (QIV) (BIOLOGICAL).

Who is sponsoring clinical trial NCT02554409?

This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02554409 being conducted?

This trial has 5 study locations across California, Florida, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pregnancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.